Concepts (264)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Substantia Nigra | 14 | 2020 | 97 | 3.740 |
Why?
|
| Glial Cell Line-Derived Neurotrophic Factor | 14 | 2014 | 53 | 3.380 |
Why?
|
| Parkinsonian Disorders | 7 | 2020 | 42 | 3.140 |
Why?
|
| Tyrosine 3-Monooxygenase | 11 | 2020 | 71 | 1.980 |
Why?
|
| Dopamine | 13 | 2019 | 467 | 1.970 |
Why?
|
| Corpus Striatum | 9 | 2019 | 270 | 1.800 |
Why?
|
| Aging | 11 | 2017 | 889 | 1.750 |
Why?
|
| Vagus Nerve Stimulation | 3 | 2020 | 54 | 1.600 |
Why?
|
| Locomotion | 5 | 2020 | 133 | 1.570 |
Why?
|
| Locus Coeruleus | 7 | 2020 | 51 | 1.500 |
Why?
|
| Glutamic Acid | 6 | 2019 | 330 | 1.430 |
Why?
|
| Dopaminergic Neurons | 4 | 2017 | 42 | 1.340 |
Why?
|
| Synaptic Transmission | 2 | 2016 | 194 | 1.080 |
Why?
|
| Motor Activity | 9 | 2015 | 603 | 0.930 |
Why?
|
| Nerve Degeneration | 5 | 2016 | 131 | 0.920 |
Why?
|
| Down Syndrome | 7 | 2019 | 119 | 0.910 |
Why?
|
| Parkinson Disease | 4 | 2019 | 247 | 0.900 |
Why?
|
| Adrenergic Neurons | 2 | 2019 | 7 | 0.890 |
Why?
|
| Neurons | 8 | 2015 | 846 | 0.860 |
Why?
|
| Receptor, trkB | 2 | 2020 | 29 | 0.830 |
Why?
|
| Animals | 41 | 2020 | 20109 | 0.810 |
Why?
|
| Brain-Derived Neurotrophic Factor | 5 | 2020 | 114 | 0.770 |
Why?
|
| Disease Models, Animal | 16 | 2020 | 2448 | 0.760 |
Why?
|
| Vagus Nerve | 1 | 2019 | 91 | 0.750 |
Why?
|
| Excitatory Amino Acid Transporter 2 | 2 | 2016 | 26 | 0.720 |
Why?
|
| Mice | 28 | 2020 | 8108 | 0.670 |
Why?
|
| Rats, Long-Evans | 5 | 2020 | 198 | 0.640 |
Why?
|
| Neurodegenerative Diseases | 4 | 2015 | 96 | 0.630 |
Why?
|
| Oxidopamine | 4 | 2020 | 43 | 0.630 |
Why?
|
| Methamphetamine | 2 | 2008 | 130 | 0.620 |
Why?
|
| Mice, Knockout | 13 | 2020 | 1649 | 0.590 |
Why?
|
| Mice, Inbred C57BL | 12 | 2020 | 2671 | 0.590 |
Why?
|
| Mitochondria | 2 | 2017 | 625 | 0.560 |
Why?
|
| Lipopolysaccharides | 2 | 2014 | 454 | 0.540 |
Why?
|
| Neostriatum | 4 | 2019 | 57 | 0.540 |
Why?
|
| Endotoxins | 1 | 2014 | 77 | 0.530 |
Why?
|
| Mice, Transgenic | 11 | 2019 | 1010 | 0.520 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 2 | 2010 | 79 | 0.510 |
Why?
|
| Norepinephrine | 5 | 2019 | 270 | 0.500 |
Why?
|
| Glial Cell Line-Derived Neurotrophic Factor Receptors | 2 | 2008 | 7 | 0.470 |
Why?
|
| Rats | 9 | 2020 | 5070 | 0.450 |
Why?
|
| Male | 28 | 2020 | 36233 | 0.430 |
Why?
|
| Receptors, Dopamine D2 | 1 | 2010 | 104 | 0.410 |
Why?
|
| Behavior, Animal | 4 | 2020 | 460 | 0.410 |
Why?
|
| Memory Disorders | 3 | 2019 | 110 | 0.410 |
Why?
|
| Brain | 6 | 2019 | 2106 | 0.390 |
Why?
|
| Diet, High-Fat | 2 | 2020 | 74 | 0.390 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2010 | 146 | 0.380 |
Why?
|
| Cognition Disorders | 4 | 2016 | 321 | 0.380 |
Why?
|
| Nucleus Accumbens | 4 | 2017 | 399 | 0.380 |
Why?
|
| 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine | 1 | 2008 | 22 | 0.370 |
Why?
|
| Minocycline | 1 | 2008 | 53 | 0.360 |
Why?
|
| Dopamine Agents | 1 | 2008 | 54 | 0.360 |
Why?
|
| Heterozygote | 4 | 2014 | 170 | 0.350 |
Why?
|
| Glial Fibrillary Acidic Protein | 3 | 2019 | 93 | 0.350 |
Why?
|
| Immunohistochemistry | 5 | 2014 | 1142 | 0.350 |
Why?
|
| Insulin Resistance | 2 | 2020 | 227 | 0.340 |
Why?
|
| Cell Count | 5 | 2015 | 251 | 0.330 |
Why?
|
| Microfilament Proteins | 2 | 2020 | 103 | 0.330 |
Why?
|
| Hippocampus | 3 | 2019 | 426 | 0.320 |
Why?
|
| Random Allocation | 3 | 2017 | 426 | 0.300 |
Why?
|
| Central Nervous System Stimulants | 1 | 2007 | 219 | 0.290 |
Why?
|
| Microglia | 3 | 2014 | 139 | 0.280 |
Why?
|
| Memory | 4 | 2017 | 217 | 0.280 |
Why?
|
| Astrocytes | 3 | 2015 | 257 | 0.260 |
Why?
|
| Gene Expression | 1 | 2006 | 755 | 0.260 |
Why?
|
| Drug-Seeking Behavior | 3 | 2017 | 206 | 0.250 |
Why?
|
| Alzheimer Disease | 3 | 2019 | 528 | 0.250 |
Why?
|
| Age Factors | 6 | 2016 | 1808 | 0.250 |
Why?
|
| Cocaine | 3 | 2017 | 536 | 0.240 |
Why?
|
| Benzylamines | 2 | 2017 | 28 | 0.210 |
Why?
|
| Cocaine-Related Disorders | 2 | 2017 | 498 | 0.210 |
Why?
|
| Neural Inhibition | 1 | 2020 | 72 | 0.200 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2016 | 506 | 0.200 |
Why?
|
| Receptor, Metabotropic Glutamate 5 | 2 | 2017 | 50 | 0.200 |
Why?
|
| Azepines | 1 | 2019 | 16 | 0.200 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2020 | 83 | 0.200 |
Why?
|
| Body Weight | 3 | 2016 | 532 | 0.190 |
Why?
|
| Calpain | 1 | 2020 | 199 | 0.190 |
Why?
|
| Electric Stimulation Therapy | 1 | 2020 | 144 | 0.180 |
Why?
|
| Motor Cortex | 1 | 2020 | 152 | 0.180 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2020 | 213 | 0.180 |
Why?
|
| Phosphorylation | 2 | 2014 | 1178 | 0.180 |
Why?
|
| Nerve Tissue Proteins | 1 | 2020 | 280 | 0.180 |
Why?
|
| Clozapine | 2 | 2015 | 44 | 0.180 |
Why?
|
| Benzamides | 1 | 2019 | 152 | 0.180 |
Why?
|
| Fluorobenzenes | 1 | 2017 | 10 | 0.180 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 2 | 2008 | 134 | 0.180 |
Why?
|
| Organelle Biogenesis | 1 | 2017 | 31 | 0.180 |
Why?
|
| Receptors, Serotonin | 1 | 2017 | 72 | 0.170 |
Why?
|
| Body Temperature | 2 | 2008 | 116 | 0.170 |
Why?
|
| Carbazoles | 1 | 2017 | 45 | 0.170 |
Why?
|
| Receptors, Somatotropin | 1 | 2017 | 4 | 0.170 |
Why?
|
| Models, Biological | 2 | 2013 | 958 | 0.170 |
Why?
|
| Nitric Oxide Synthase Type I | 1 | 2017 | 36 | 0.160 |
Why?
|
| Extinction, Psychological | 2 | 2015 | 227 | 0.160 |
Why?
|
| Potassium Chloride | 1 | 2016 | 45 | 0.160 |
Why?
|
| Interneurons | 1 | 2017 | 41 | 0.160 |
Why?
|
| Dysbindin | 1 | 2016 | 9 | 0.160 |
Why?
|
| Recovery of Function | 1 | 2020 | 492 | 0.160 |
Why?
|
| Fingolimod Hydrochloride | 1 | 2016 | 24 | 0.160 |
Why?
|
| Maze Learning | 5 | 2016 | 133 | 0.160 |
Why?
|
| Diet, Western | 1 | 2016 | 17 | 0.160 |
Why?
|
| Neurotransmitter Agents | 1 | 2016 | 95 | 0.150 |
Why?
|
| Anesthetics | 1 | 2016 | 31 | 0.150 |
Why?
|
| Midazolam | 1 | 2016 | 42 | 0.150 |
Why?
|
| Indans | 1 | 2015 | 20 | 0.150 |
Why?
|
| Exosomes | 1 | 2016 | 50 | 0.150 |
Why?
|
| Stroke Rehabilitation | 1 | 2020 | 324 | 0.150 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 2 | 2016 | 226 | 0.150 |
Why?
|
| Cognition | 2 | 2017 | 479 | 0.150 |
Why?
|
| Synapses | 2 | 2015 | 174 | 0.150 |
Why?
|
| Analysis of Variance | 2 | 2008 | 1021 | 0.150 |
Why?
|
| Receptor, Muscarinic M3 | 1 | 2015 | 8 | 0.150 |
Why?
|
| Synaptosomes | 2 | 2016 | 59 | 0.150 |
Why?
|
| Subthalamic Nucleus | 1 | 2014 | 15 | 0.140 |
Why?
|
| Kinetics | 1 | 2016 | 1032 | 0.140 |
Why?
|
| Neuroimaging | 1 | 2016 | 113 | 0.140 |
Why?
|
| Potassium | 2 | 2014 | 166 | 0.140 |
Why?
|
| Heroin Dependence | 1 | 2014 | 20 | 0.140 |
Why?
|
| Neuroimmunomodulation | 1 | 2014 | 16 | 0.130 |
Why?
|
| Estrogen Receptor alpha | 1 | 2014 | 64 | 0.130 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2014 | 41 | 0.130 |
Why?
|
| Image Enhancement | 1 | 2014 | 140 | 0.130 |
Why?
|
| Heroin | 1 | 2014 | 39 | 0.130 |
Why?
|
| Calcium-Binding Proteins | 1 | 2014 | 108 | 0.130 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2015 | 156 | 0.130 |
Why?
|
| Neuroglia | 1 | 2014 | 134 | 0.130 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2014 | 164 | 0.120 |
Why?
|
| Obesity | 1 | 2020 | 1015 | 0.120 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2014 | 232 | 0.120 |
Why?
|
| Immunosuppressive Agents | 1 | 2016 | 485 | 0.120 |
Why?
|
| Antipsychotic Agents | 1 | 2015 | 243 | 0.120 |
Why?
|
| Superoxide Dismutase | 1 | 2013 | 137 | 0.120 |
Why?
|
| Cyclooxygenase 2 | 1 | 2013 | 161 | 0.120 |
Why?
|
| Down-Regulation | 2 | 2014 | 445 | 0.110 |
Why?
|
| Metabolic Clearance Rate | 1 | 2010 | 51 | 0.110 |
Why?
|
| Vesicular Monoamine Transport Proteins | 1 | 2010 | 9 | 0.110 |
Why?
|
| Walking | 1 | 2013 | 225 | 0.110 |
Why?
|
| Synaptic Vesicles | 1 | 2010 | 18 | 0.110 |
Why?
|
| Recombinant Proteins | 1 | 2013 | 732 | 0.110 |
Why?
|
| Memantine | 1 | 2010 | 7 | 0.100 |
Why?
|
| Microdialysis | 1 | 2010 | 146 | 0.100 |
Why?
|
| Extracellular Space | 1 | 2010 | 119 | 0.100 |
Why?
|
| Cholinergic Fibers | 1 | 2010 | 28 | 0.100 |
Why?
|
| Rats, Sprague-Dawley | 4 | 2017 | 1977 | 0.100 |
Why?
|
| Gene Expression Regulation | 3 | 2016 | 1264 | 0.100 |
Why?
|
| Cell Survival | 3 | 2008 | 890 | 0.100 |
Why?
|
| Postural Balance | 1 | 2010 | 92 | 0.100 |
Why?
|
| Self Administration | 3 | 2017 | 403 | 0.100 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2010 | 390 | 0.100 |
Why?
|
| Female | 9 | 2020 | 39962 | 0.100 |
Why?
|
| Photomicrography | 1 | 2008 | 13 | 0.090 |
Why?
|
| Conditioning, Operant | 2 | 2014 | 231 | 0.090 |
Why?
|
| Leukocyte Common Antigens | 1 | 2008 | 37 | 0.090 |
Why?
|
| Encephalitis | 1 | 2008 | 40 | 0.090 |
Why?
|
| Oxidative Stress | 1 | 2013 | 696 | 0.090 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2014 | 712 | 0.090 |
Why?
|
| Designer Drugs | 2 | 2019 | 7 | 0.090 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2010 | 624 | 0.090 |
Why?
|
| Serotonin | 1 | 2007 | 141 | 0.080 |
Why?
|
| Signal Transduction | 1 | 2017 | 2599 | 0.080 |
Why?
|
| Mesencephalon | 1 | 2006 | 40 | 0.080 |
Why?
|
| Affect | 1 | 2008 | 215 | 0.080 |
Why?
|
| Urea | 1 | 2006 | 56 | 0.080 |
Why?
|
| Animals, Newborn | 1 | 2007 | 384 | 0.080 |
Why?
|
| Rats, Inbred F344 | 2 | 2016 | 102 | 0.080 |
Why?
|
| Creatinine | 1 | 2006 | 238 | 0.080 |
Why?
|
| Axons | 1 | 2006 | 131 | 0.080 |
Why?
|
| Ceftriaxone | 2 | 2015 | 31 | 0.070 |
Why?
|
| Time Factors | 1 | 2014 | 4527 | 0.070 |
Why?
|
| Pregnancy | 1 | 2010 | 2231 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 705 | 0.070 |
Why?
|
| Genotype | 1 | 2006 | 740 | 0.070 |
Why?
|
| Reward | 1 | 2005 | 197 | 0.070 |
Why?
|
| Nerve Growth Factors | 1 | 2004 | 75 | 0.060 |
Why?
|
| Excitatory Amino Acid Antagonists | 2 | 2017 | 126 | 0.060 |
Why?
|
| Multivariate Analysis | 1 | 2006 | 1038 | 0.060 |
Why?
|
| Mice, Inbred C3H | 2 | 2014 | 135 | 0.060 |
Why?
|
| Models, Animal | 2 | 2017 | 251 | 0.060 |
Why?
|
| RNA, Messenger | 1 | 2006 | 1601 | 0.060 |
Why?
|
| Kidney | 1 | 2006 | 921 | 0.050 |
Why?
|
| Forelimb | 1 | 2020 | 15 | 0.050 |
Why?
|
| Adipose Tissue, White | 1 | 2020 | 7 | 0.050 |
Why?
|
| Adipose Tissue, Brown | 1 | 2020 | 8 | 0.050 |
Why?
|
| Adiponectin | 1 | 2020 | 47 | 0.050 |
Why?
|
| Physical Exertion | 1 | 2020 | 73 | 0.050 |
Why?
|
| Leptin | 1 | 2020 | 77 | 0.050 |
Why?
|
| Fatty Liver | 1 | 2020 | 95 | 0.050 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2020 | 124 | 0.050 |
Why?
|
| Vesicular Glutamate Transport Protein 1 | 1 | 2019 | 2 | 0.050 |
Why?
|
| Energy Metabolism | 1 | 2020 | 219 | 0.040 |
Why?
|
| Lymphocyte Activation | 1 | 2020 | 397 | 0.040 |
Why?
|
| Algorithms | 2 | 2014 | 1159 | 0.040 |
Why?
|
| Mice, 129 Strain | 1 | 2017 | 40 | 0.040 |
Why?
|
| Spatial Learning | 1 | 2017 | 16 | 0.040 |
Why?
|
| Excitatory Amino Acid Agonists | 1 | 2017 | 59 | 0.040 |
Why?
|
| Intra-Abdominal Fat | 1 | 2016 | 11 | 0.040 |
Why?
|
| Voltage-Dependent Anion Channel 2 | 1 | 2016 | 9 | 0.040 |
Why?
|
| tau Proteins | 1 | 2016 | 53 | 0.040 |
Why?
|
| Voltage-Dependent Anion Channel 1 | 1 | 2016 | 10 | 0.040 |
Why?
|
| Neuropathology | 1 | 2016 | 2 | 0.040 |
Why?
|
| Chaperonin 60 | 1 | 2015 | 10 | 0.040 |
Why?
|
| Synapsins | 1 | 2015 | 11 | 0.040 |
Why?
|
| Monoamine Oxidase | 1 | 2015 | 27 | 0.040 |
Why?
|
| Animals, Genetically Modified | 1 | 2015 | 59 | 0.040 |
Why?
|
| Monoamine Oxidase Inhibitors | 1 | 2015 | 31 | 0.040 |
Why?
|
| Organ Size | 1 | 2016 | 236 | 0.040 |
Why?
|
| SNARE Proteins | 1 | 2015 | 6 | 0.040 |
Why?
|
| Calcium Channels, N-Type | 1 | 2015 | 7 | 0.040 |
Why?
|
| Mice, Neurologic Mutants | 1 | 2015 | 23 | 0.040 |
Why?
|
| Dietary Sucrose | 1 | 2015 | 18 | 0.040 |
Why?
|
| Social Behavior | 1 | 2016 | 158 | 0.040 |
Why?
|
| Amyloid beta-Peptides | 1 | 2016 | 174 | 0.040 |
Why?
|
| Serine | 1 | 2015 | 99 | 0.040 |
Why?
|
| Central Nervous System Agents | 1 | 2015 | 37 | 0.040 |
Why?
|
| Humans | 5 | 2016 | 68792 | 0.030 |
Why?
|
| Morpholinos | 1 | 2014 | 6 | 0.030 |
Why?
|
| Receptors, Metabotropic Glutamate | 1 | 2015 | 74 | 0.030 |
Why?
|
| Exploratory Behavior | 1 | 2015 | 73 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2015 | 256 | 0.030 |
Why?
|
| Neural Pathways | 2 | 2008 | 308 | 0.030 |
Why?
|
| Peptide Fragments | 1 | 2016 | 468 | 0.030 |
Why?
|
| Excitatory Postsynaptic Potentials | 1 | 2014 | 71 | 0.030 |
Why?
|
| Aspartic Acid | 1 | 2014 | 63 | 0.030 |
Why?
|
| Recurrence | 1 | 2017 | 924 | 0.030 |
Why?
|
| Actigraphy | 1 | 2013 | 27 | 0.030 |
Why?
|
| Head | 1 | 2013 | 54 | 0.030 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2015 | 148 | 0.030 |
Why?
|
| In Vitro Techniques | 1 | 2014 | 728 | 0.030 |
Why?
|
| Cerebral Cortex | 1 | 2016 | 411 | 0.030 |
Why?
|
| Genetic Therapy | 1 | 2015 | 291 | 0.030 |
Why?
|
| Neuroprotective Agents | 1 | 2015 | 311 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2017 | 1720 | 0.030 |
Why?
|
| Secondary Prevention | 1 | 2014 | 288 | 0.030 |
Why?
|
| Biomechanical Phenomena | 1 | 2013 | 360 | 0.030 |
Why?
|
| Calcium | 1 | 2016 | 898 | 0.030 |
Why?
|
| Mutation | 1 | 2016 | 1184 | 0.030 |
Why?
|
| Biomarkers | 1 | 2016 | 1541 | 0.030 |
Why?
|
| Chromosomes, Mammalian | 1 | 2010 | 8 | 0.030 |
Why?
|
| Liver | 1 | 2016 | 1081 | 0.030 |
Why?
|
| Trisomy | 1 | 2010 | 44 | 0.030 |
Why?
|
| Mice, Mutant Strains | 1 | 2010 | 165 | 0.030 |
Why?
|
| Cues | 1 | 2015 | 654 | 0.030 |
Why?
|
| Presynaptic Terminals | 1 | 2008 | 21 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 2019 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2010 | 547 | 0.020 |
Why?
|
| Apoptosis | 1 | 2016 | 1613 | 0.020 |
Why?
|
| Dopamine Agonists | 1 | 2008 | 69 | 0.020 |
Why?
|
| Receptors, Dopamine D1 | 1 | 2008 | 84 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 4741 | 0.020 |
Why?
|
| Growth Cones | 1 | 2006 | 6 | 0.020 |
Why?
|
| Organ Culture Techniques | 1 | 2006 | 109 | 0.020 |
Why?
|
| Cell Communication | 1 | 2006 | 117 | 0.020 |
Why?
|
| Sucrose | 1 | 2005 | 53 | 0.020 |
Why?
|
| Young Adult | 1 | 2016 | 5496 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2008 | 745 | 0.020 |
Why?
|
| Brain Tissue Transplantation | 1 | 2004 | 11 | 0.020 |
Why?
|
| Fetal Tissue Transplantation | 1 | 2004 | 13 | 0.020 |
Why?
|
| Cell Movement | 1 | 2006 | 611 | 0.020 |
Why?
|
| Adolescent | 1 | 2016 | 8641 | 0.020 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2004 | 320 | 0.010 |
Why?
|
| Depression | 1 | 2008 | 923 | 0.010 |
Why?
|
| Middle Aged | 1 | 2016 | 20597 | 0.010 |
Why?
|